Anixa starts subject treatment in Phase I ovarian cancer cell therapy trial

cafead

Administrator
Staff member
  • cafead   Aug 16, 2022 at 11:22: AM
via Anixa Biosciences and its partner Moffitt Cancer Center have initiated treatment of the first subject in the Phase I clinical trial of new chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.

article source
 

<